Skip to main content

Table 1 Baseline characteristics of the patients

From: The association between prothrombin time-international normalized ratio and long-term mortality in patients with coronary artery disease: a large cohort retrospective study with 44,662 patients

Characteristic PT-INR level quartile
Overall  ≤ 0.96 0.96–1.01 1.01–1.06  > 1.06 p Value
(n = 44,662) (n = 12,014) (n = 12,389) (n = 9936) (n = 10,323)
Demographic
Age, year 62.96 (10.71) 60.98 (10.15) 62.31 (10.54) 63.75 (10.72) 65.28 (11.01)  < 0.001
Male, n (%) 33,938 (75.99) 8583 (71.44) 9353 (75.49) 7688 (77.38) 8314 (80.54)  < 0.001
Medical history
AMI, n (%) 8544 (19.15) 1447 (12.06) 1931 (15.60) 1973 (19.88) 3193 (30.98)  < 0.001
CHF, n (%) 3830 (8.58) 601 (5.01) 761 (6.15) 820 (8.26) 1648 (15.98)  < 0.001
Hypertension, n (%) 25,415 (56.98) 6920 (57.68) 7021 (56.74) 5732 (57.76) 5742 (55.70) 0.007
DM, n (%) 12,423 (27.85) 3582 (29.85) 3384 (27.35) 2564 (25.84) 2893 (28.07)  < 0.001
PCI, n (%) 33,284 (74.52) 8746 (72.80) 9142 (73.79) 7464 (75.12) 7932 (76.84)  < 0.001
CKD, n (%) 7833 (21.56) 1479 (15.49) 1803 (18.18) 1764 (21.77) 2787 (31.79)  < 0.001
Laboratory test
INR 1.02 (0.13) 0.93 (0.03) 0.99 (0.01) 1.04 (0.01) 1.15 (0.20)  < 0.001
D-dimer (ng/mL) 624.48 (1256.03) 474.66 (810.95) 514.92 (863.34) 605.73 (1116.67) 949.80 (1956.06)  < 0.001
FIB, g/L 4.12 (1.28) 4.03 (1.04) 4.07 (1.18) 4.14 (1.31) 4.26 (1.59)  < 0.001
ALT (U/L) 34.36 (84.89) 31.91 (28.61) 30.99 (54.32) 30.65 (31.11) 44.78 (159.84)  < 0.001
AST (U/L) 48.92 (196.68) 33.70 (44.46) 36.43 (55.56) 42.20 (70.42) 88.06 (393.12)  < 0.001
WBC, 109/L 7.97 (2.71) 7.73 (2.14) 7.73 (2.31) 7.84 (2.60) 8.67 (3.59)  < 0.001
HGB, g/L 133.13 (16.75) 136.64 (14.81) 134.83 (15.58) 132.29 (16.44) 127.82 (18.98)  < 0.001
CHOL, mmol/L 4.54 (1.21) 4.87 (1.27) 4.59 (1.18) 4.41 (1.13) 4.21 (1.14)  < 0.001
TRIG, mmol/L 1.67 (1.22) 2.05 (1.68) 1.69 (1.11) 1.53 (0.93) 1.34 (0.76)  < 0.001
LDLC, mmol/L 2.80 (0.97) 2.97 (1.01) 2.84 (0.97) 2.73 (0.93) 2.63 (0.94)  < 0.001
HDLC, mmol/L 1.00 (0.26) 1.04 (0.27) 1.00 (0.25) 0.98 (0.25) 0.95 (0.25)  < 0.001
HbA1c, % 6.56 (1.42) 6.69 (1.52) 6.53 (1.38) 6.51 (1.39) 6.50 (1.37)  < 0.001
URIC, μmol/L 393.52 (110.49) 393.45 (102.21) 389.57 (102.89) 390.74 (109.23) 401.10 (128.07)  < 0.001
eGFR, ml/min/1.73 m2 77.95 (25.22) 82.87 (25.19) 79.64 (23.69) 77.33 (24.39) 71.25 (26.18)  < 0.001
ALB, g/L 36.37 (4.22) 37.40 (3.79) 36.93 (3.88) 36.31 (4.03) 34.55 (4.65)  < 0.001
Hs-CRP, mg/L 12.07(22.75) 6.24 (11.82) 8.66 (18.00) 11.60 (23.36) 23.40 (40.60)  < 0.001
Medication
Antiplatelet, n (%) 42,965 (97.41) 11,606 (97.34) 11,945 (97.24) 9596 (97.59) 9818 (97.54) 0.318
ACEI/ARB, n (%) 22,110 (50.13) 5801 (48.65) 6130 (49.90) 4942 (50.26) 5237 (52.03)  < 0.001
Beta-blockers, n (%) 35,957 (81.52) 9804 (82.23) 10,039 (81.72) 8008 (81.44) 8106 (80.53) 0.012
Statin, n (%) 42,274 (95.85) 11,488 (96.35) 11,812 (96.16) 9434 (95.94) 9540 (94.77)  < 0.001
Death, n (%) 5613 (12.57) 1116 (9.29) 1426 (11.51) 1249 (12.57) 1822 (17.65)  < 0.001
  1. AMI acute myocardial infarction, CHF congestive heart failure, DM diabetes mellitus, PCI percutaneous coronary intervention, CKD chronic kidney disease, WBC white blood cell, HGB hemoglobin, CHOL serum total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C hight-density lipoprotein cholesterol, HbA1c Glycated hemoglobin, eGFR estimated glomerular filtration rate, ALB albumin, Hs-CRP hypersensitive C-reactive protein, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, AST aspartate transaminase, ALT alanine aminotransferase, FIB fibrinogen